[go: up one dir, main page]

AU2001264559A1 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets

Info

Publication number
AU2001264559A1
AU2001264559A1 AU2001264559A AU6455901A AU2001264559A1 AU 2001264559 A1 AU2001264559 A1 AU 2001264559A1 AU 2001264559 A AU2001264559 A AU 2001264559A AU 6455901 A AU6455901 A AU 6455901A AU 2001264559 A1 AU2001264559 A1 AU 2001264559A1
Authority
AU
Australia
Prior art keywords
gene
determination
signature
therapeutic screening
sets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264559A
Other versions
AU2001264559A8 (en
Inventor
Meena Augustus
Kenneth C. Carter
Reinhard Ebner
Greg Endress
Steve Horrigan
Daniel R Soppet
Zoe Weaver
Paul E. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Publication of AU2001264559A1 publication Critical patent/AU2001264559A1/en
Publication of AU2001264559A8 publication Critical patent/AU2001264559A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001264559A 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets Abandoned AU2001264559A1 (en)

Applications Claiming Priority (85)

Application Number Priority Date Filing Date Title
US20953100P 2000-06-05 2000-06-05
US20947300P 2000-06-05 2000-06-05
US60/209,531 2000-06-05
US60/209,473 2000-06-05
US23361700P 2000-09-18 2000-09-18
US23313300P 2000-09-18 2000-09-18
US60/233,617 2000-09-18
US60/233,133 2000-09-18
US23405200P 2000-09-20 2000-09-20
US23403400P 2000-09-20 2000-09-20
US23400900P 2000-09-20 2000-09-20
US60/234,009 2000-09-20
US60/234,052 2000-09-20
US60/234,034 2000-09-20
US23450900P 2000-09-22 2000-09-22
US23456700P 2000-09-22 2000-09-22
US60/234,567 2000-09-22
US60/234,509 2000-09-22
US23507700P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23492300P 2000-09-25 2000-09-25
US23513400P 2000-09-25 2000-09-25
US23492400P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US60/235,134 2000-09-25
US60/235,077 2000-09-25
US60/234,924 2000-09-25
US60/235,082 2000-09-25
US60/235,280 2000-09-25
US60/234,923 2000-09-25
US23563800P 2000-09-26 2000-09-26
US23563700P 2000-09-26 2000-09-26
US60/235,637 2000-09-26
US60/235,638 2000-09-26
US23584000P 2000-09-27 2000-09-27
US23571100P 2000-09-27 2000-09-27
US23572000P 2000-09-27 2000-09-27
US23586300P 2000-09-27 2000-09-27
US60/235,840 2000-09-27
US60/235,863 2000-09-27
US60/235,711 2000-09-27
US60/235,720 2000-09-27
US23602800P 2000-09-28 2000-09-28
US23603300P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US23603400P 2000-09-28 2000-09-28
US23603200P 2000-09-28 2000-09-28
US60/236,033 2000-09-28
US60/236,111 2000-09-28
US60/236,109 2000-09-28
US60/236,032 2000-09-28
US60/236,034 2000-09-28
US60/236,028 2000-09-28
US23689100P 2000-09-29 2000-09-29
US23684200P 2000-09-29 2000-09-29
US60/236,891 2000-09-29
US60/236,842 2000-09-29
US23729500P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23729400P 2000-10-02 2000-10-02
US23727800P 2000-10-02 2000-10-02
US23731600P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US60/237,278 2000-10-02
US60/237,294 2000-10-02
US60/237,173 2000-10-02
US60/237,295 2000-10-02
US60/237,316 2000-10-02
US60/237,172 2000-10-02
US23759800P 2000-10-03 2000-10-03
US23742500P 2000-10-03 2000-10-03
US23760800P 2000-10-03 2000-10-03
US23760600P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US60/237,604 2000-10-03
US60/237,608 2000-10-03
US60/237,606 2000-10-03
US60/237,598 2000-10-03
US60/237,425 2000-10-03
US24508400P 2000-11-01 2000-11-01
US24486700P 2000-11-01 2000-11-01
US60/244,867 2000-11-01
US60/245,084 2000-11-01
PCT/US2001/010838 WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Publications (2)

Publication Number Publication Date
AU2001264559A1 true AU2001264559A1 (en) 2001-12-17
AU2001264559A8 AU2001264559A8 (en) 2001-12-17

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264559A Abandoned AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US20040219569A1 (en) 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
EP1623992A3 (en) * 1999-09-01 2006-05-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1228208T3 (en) 1999-10-28 2010-11-22 Agensys Inc 36P6D5: secreted tumor antigen
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
EP1265913A4 (en) 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF LIGANDS-GRP94 INTERACTIONS AND RELATED PURIFICATION, SCREENING AND PROCESSING METHODS
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
AU2001251034A1 (en) * 2000-03-31 2001-10-15 Gene Logic, Inc Gene expression profiles in esophageal tissue
JP4750999B2 (en) * 2000-03-31 2011-08-17 アベンティス・ファーマスーティカルズ・インコーポレイテツド Nuclear factor κB inducer
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
EP1666491A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002012339A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
WO2002044357A2 (en) * 2000-11-30 2002-06-06 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
CA2431313A1 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20020137184A1 (en) * 2000-12-20 2002-09-26 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
CA2437750A1 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2439630A1 (en) * 2001-03-23 2002-10-03 Agy Therapeutics Use of biomolecular targets in the treatment and visualization of brain tumors
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
ATE478147T1 (en) * 2001-05-31 2010-09-15 Chiba Prefecture NUCLEIC ACIDS ISOLATED FROM A NEUROBLASTOMA
JP2005505257A (en) * 2001-06-05 2005-02-24 エクセリクシス・インコーポレイテッド IGs as p53 pathway modifiers and methods of use
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2633595A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003099318A2 (en) 2002-05-29 2003-12-04 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pancreas-specific proteins
JP2005508160A (en) * 2001-09-18 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Human tyrosine phosphatase family member MID4460 and uses thereof
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003046581A2 (en) * 2001-11-27 2003-06-05 Oxford Glycosciences (Uk) Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
AU2003210554A1 (en) * 2002-01-18 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
US20060089320A1 (en) * 2002-02-01 2006-04-27 Cantley Lewis C Modulation of type IIß phosphoinositide phosphate kinase
EP1487991A4 (en) * 2002-03-06 2006-06-14 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
CA2413475C (en) 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
EP1510587B1 (en) * 2002-05-21 2011-07-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
WO2003105758A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105783A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003246592A1 (en) * 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0216727D0 (en) * 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
JPWO2004016784A1 (en) * 2002-08-06 2005-12-02 株式会社ジェノックス創薬研究所 Protease inhibitor
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
EP1557466B1 (en) * 2002-09-27 2009-09-02 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and utilization thereof
WO2005090991A1 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004031411A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US20060015951A1 (en) * 2002-10-14 2006-01-19 Karsten Eulenberg Proteins involved in the regulation of energy homeostasis
AU2003279312A1 (en) * 2002-10-24 2004-05-13 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US7425624B1 (en) * 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
US20040146921A1 (en) * 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
CN101265503A (en) * 2003-03-10 2008-09-17 独立行政法人科学技术振兴机构 Marker for detection of mesenchymal stem cells and method for identifying mesenchymal stem cells using the marker
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
CN1791683A (en) * 2003-05-21 2006-06-21 弗·哈夫曼-拉罗切有限公司 Markers for LXR activation
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
KR20060034231A (en) 2003-06-06 2006-04-21 메디뮨 인코포레이티드 Use of EPH4 and EPH4 modulators in the diagnosis, treatment and prevention of cancer
WO2005010213A2 (en) * 2003-07-17 2005-02-03 Pacific Edge Biotechnology, Ltd. Markers for detection of gastric cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
JP2007502119A (en) * 2003-08-14 2007-02-08 エクセリクシス， インク． UPs as β-catenin pathway modifiers and methods of use
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
CA2549324A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
AU2004298604B2 (en) * 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP4938451B2 (en) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 Methods for diagnosis of non-small cell lung cancer
JP2007532111A (en) * 2004-04-06 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Orphan receptor tyrosine kinase as a target in breast cancer
EP1733743A4 (en) * 2004-04-09 2007-06-27 Takeda Pharmaceutical PREVENTION AGENTS / REMEDIES AGAINST CANCER
PT1742966E (en) 2004-04-22 2014-02-05 Agensys Inc Antibodies and molecules derived therefrom that bind to steap-1 proteins
AU2005241093B2 (en) * 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
WO2005118869A2 (en) * 2004-05-28 2005-12-15 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
MXPA06014116A (en) 2004-06-04 2007-08-08 Aviaradx Inc Identification of tumors.
DE602005013998D1 (en) * 2004-06-25 2009-05-28 Veridex Llc METHOD AND REAGENTS FOR DETECTING MELANOMA
US20080254031A1 (en) * 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
US20080145369A1 (en) * 2004-10-13 2008-06-19 Ginette Serrero Autocrine Growth Factor Receptors and Methods
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human primary cancer gene, protein encoded thereby
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
DK1899484T3 (en) 2005-06-03 2015-11-23 Biotheranostics Inc Identification of tumors and tissues
US8716021B2 (en) 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2007048978A2 (en) * 2005-10-28 2007-05-03 Biomerieux Sa Method for detecting cancer
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
CN101437962A (en) * 2006-03-03 2009-05-20 维里德克斯有限责任公司 Molecular assay to predict recurrence of duke's B colon cancer
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
AR053600A1 (en) * 2006-04-28 2007-05-09 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM THE A33 HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
JPWO2008029601A1 (en) * 2006-08-16 2010-01-21 株式会社 未来創薬研究所 Cancer therapeutic agent comprising as an active ingredient a ligand for neuromedin U receptor 2 (FM4) molecule
MX2009003938A (en) 2006-10-27 2009-04-24 Genentech Inc Antibodies and immunoconjugates and uses therefor.
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
ES2417148T3 (en) * 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2008286333B2 (en) * 2007-08-14 2013-11-14 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
CN102099485A (en) * 2007-10-23 2011-06-15 临床基因组学有限公司 Methods for diagnosing neoplasms-Ⅱ
CN102027128A (en) * 2008-02-11 2011-04-20 哈达斯特医学服务与开发有限公司 Colon cancer associated transcript 1 (CCAT-1) as a cancer marker
DK2276509T3 (en) 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CN102076865B (en) 2008-05-02 2016-03-16 西雅图基因公司 The antibody reduced for the manufacture of core fucosylation and the method and composition of antibody derivatives
US9260499B2 (en) 2008-10-20 2016-02-16 Sapporo Medical University Tumor antigen peptide and use thereof
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016083360A1 (en) * 2014-11-25 2016-06-02 Ait Austrian Institute Of Technology Gmbh Diagnosis of lung cancer
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
AU2019347666B2 (en) 2018-09-28 2025-10-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
AU757478C (en) * 1998-03-31 2004-03-25 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Also Published As

Publication number Publication date
JP2004509612A (en) 2004-04-02
WO2001094629A8 (en) 2002-05-16
WO2001094629A3 (en) 2003-09-04
CA2411601A1 (en) 2001-12-13
EP1358349A2 (en) 2003-11-05
WO2001094629A2 (en) 2001-12-13
AU2001264559A8 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU3869400A (en) Human cancer associated gene sequences and polypeptides
AU2003215460A1 (en) Cancer associated protein kinases and their uses
AU2002311869A1 (en) Breast cancer-associated genes and uses thereof
EP1466982A4 (en) Pyroglutamyl peptidase and its gene
AU2002319338A1 (en) Cancer specific oligosaccharide sequences and use thereof
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2003212162A1 (en) Cancer associated protein phosphatases and their uses
AU2001226922A1 (en) Cancer associated genes and their products
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2002303262A1 (en) Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2002364077A1 (en) Gene expression profiles in stomach cancer
AU2002366364A1 (en) E2f and cancer therapy
AU2002305138A1 (en) Methods and materials for cancer treatment
AU3524500A (en) (rab) genes and their uses
AU2002240921A1 (en) Medane genes and proteins
AU2002335796A1 (en) Tumor endothelial marker 5alpha molecules and uses thereof
AU2002953516A0 (en) Genetic therapy and genetic modification
AU2001237414A1 (en) Cancer treatment and prognosis